T5451
Tissue plasminogen activator human
pkg of 10 μg, ≥400,000 IU/mg (activity expressed per mg of tPA)
Synonym(s):
tPA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
recombinant
expressed in CHO cells
form
lyophilized powder
specific activity
≥400,000 IU/mg (activity expressed per mg of tPA)
mol wt
~70 kDa
packaging
pkg of 10 μg
UniProt accession no.
storage temp.
2-8°C
Gene Information
human ... PLAT(5327)
Looking for similar products? Visit Product Comparison Guide
Application
Tissue plasminogen activator has been used in a study to assess treatment risks of intracranial hemorrhage among patients with acute ischemic stroke. [1] Tissue plasminogen activator has also been used in a study to investigate the successful treatment of early thrombosis of HeartWare left ventricular assist devices with intraventricular thrombolytics. [2]
Physical form
Supplied as lyophilized powder containing 10 μg tPA lyophilized from a 100 μg/ml solution containing 1 M NH4HCO4 with 1% bovine serum albumin.
Tissue Plasminogen Activator (tPA) is a protease of the S1 family (trypsin family) and is found in a wide variety of mammalian tissues, especially endothelial cells. tPA is secreted as a single chain precursor, which is cleaved to a two-chain form by plasmin. Supplied in the single chain form with a molecular weight of ~70 kDa.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator
Xian, Y., et al.
Journal of the American Medical Association, 307, 2600-2608 (2012)
Abdallah Kamouh et al.
The Annals of thoracic surgery, 94(1), 281-283 (2012-06-28)
In the last few years, left ventricular assist devices (LVADs) have moved to the forefront in the management of patients with advanced heart failure. Pumps have gradually become smaller and more efficient and have clearly demonstrated survival benefits and improvement
Dan Huang et al.
Frontiers of medicine, 11(3), 410-422 (2017-07-09)
Aberrant expression of annexin A2-S100A10 heterotetramer (AIIt) associated with PML/RARα fusion protein causes lethal hyperfibrinolysis in acute promyelocytic leukemia (APL), but the mechanism is unclear. To facilitate the investigation of regulatory association between ANXA2 and promyelocytic leukemia/retinoic acid receptor a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
